secwatch.observer — SEC 8-K summary
======================================

Issuer:     BullFrog AI Holdings, Inc. (BFRG)
CIK:        0001829247
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001493152-25-008518
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bullfrog AI enters collaboration with Eleison to optimize Phase 3 pancreatic cancer trial
--------------------------------------------------------------------------------

- Collaboration announced Feb 27, 2025; Bullfrog AI to apply bfLEAP platform to Eleison's glufosfamide Phase 3 trial.
- Bullfrog Data Networks will analyze safety signals and extract predictive biomarkers from prior and ongoing studies.
- Eleison's ongoing glufosfamide Phase 3 trial targets second-line pancreatic cancer; expected completion in 2027.
- Financial terms of the agreement were not disclosed.
- Partnership also covers Eleison's pipeline programs ILC (lung cancer) and DBD (brain cancers).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829247/000149315225008518/0001493152-25-008518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829247/000149315225008518/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-008518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer